Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

This study is an umbrella trial for patients with advanced (stage III, unresectable) non-small cell lung cancer (NSCLC) who have rare genetic mutations in their tumors. Each patient is matched to a targeted therapy based on their specific mutation. The goal is to determine whether matching treatment to the mutation improves outcomes. **You may be eligible if...** - You are age 18–75 with stage III NSCLC that cannot be surgically removed - Your tumor has been tested with a genetic panel (NGS) and carries a rare mutation such as EGFR exon 20 insertion, ROS1, RET, NTRK, MET, HER2, BRAF V600E, KRAS G12C, or ALK fusion - You have not had any prior systemic treatment for lung cancer - You are in good general health (ECOG 0–1) **You may NOT be eligible if...** - Your tumor has a common EGFR mutation (exon 19 deletion or L858R) - Your lung cancer has already been treated with systemic therapy - You are pregnant or breastfeeding - You have significant inflammation in your eyes Talk to your doctor to see if this trial is right for you.